Key Points {#FPar10}
==========

Polypharmacy is an urgent issue that requires a co-ordinated global effort to provide medical care systems that better serve patients with multimorbidity.This transition requires a shift in medical education, research, and diagnostic frameworks, and reexamination of the measures used as quality indicators.This position statement from the International Group for Reducing Inappropriate Medication Use & Polypharmacy briefly summarizes the current situation and provides a call to action for moving forward, proposing 10 recommendations for action and 12 recommendations for research.

Background and Objectives {#Sec1}
=========================

Over recent decades, the number of drug prescriptions has increased globally. As a result of their increased number of chronic diseases and geriatric syndromes, older adults are the main drug users, consuming over one-third of medications used in the USA \[[@CR1], [@CR2]\]. Compared with a younger population, older adults are at higher risk of medication-related adverse events \[[@CR3]\]. Vulnerability characteristics such as very old age, multiple co-morbidities, dementia, frailty, and limited life expectancy markedly alter the risk--benefit balance of medications. These characteristics are often accompanied by impaired medication clearance and reduced physiological reserve \[[@CR4]\] and, in combination with polypharmacy (traditionally understood as taking five or more long-term medications), significantly reduce benefit and amplify the risk of most drug therapies, thus making adverse drug events (ADEs) and inappropriate medication use almost inevitable. There is a robust literature and reviews that already describe the negative medical, economic, and social consequences of inappropriate medication use and polypharmacy (IMUP), which are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Negative outcomes and hazards of inappropriate medication use and polypharmacy1.Drug-specific adverse effects2.Drug--drug interaction3.Drug--disease interaction4.Cognitive impairment/delirium \[[@CR5]--[@CR8]\]5.Weight loss, malnutrition \[[@CR9], [@CR10]\]6.Falls \[[@CR11]--[@CR15]\]7.Hip fractures \[[@CR12]\]8.Urinary incontinence \[[@CR16]\]9.Functional impairment, immobility \[[@CR17], [@CR18]\]10.Hospitalization \[[@CR17], [@CR19]--[@CR26]\]11.Nursing home, long-term care placement \[[@CR20]--[@CR24], [@CR27]\]12.Decrease in quality of life \[[@CR27]\]13.Death \[[@CR27]\]14.Reduced treatment adherence \[[@CR28]\]15.Increased cost to the health system and to the individual \[[@CR17], [@CR20]--[@CR24], [@CR29]--[@CR36]\]

Many risk factors, such as elevated cholesterol, glucose, and blood pressure, lose much of their negative portent in older age \[[@CR37]--[@CR39]\] and some risk factors reverse to become predictors of better outcomes. Therefore, treating marker-defined conditions to target goals developed for younger people may be ineffective or, worse, damaging \[[@CR26], [@CR40]--[@CR42]\].

While noting the importance and risks of under-prescribing in some settings, the focus of this position paper is over-prescribing. Medical errors, including ADEs are now leading causes of death, with many events yet to be recognized \[[@CR24], [@CR43], [@CR44]\]. These casualties are on the scale of a war or epidemic; yet, this iatrogenic 'epidemic' is nearly invisible in guideline recommendations and quality measures. Just as with a war or epidemic, radical and rapid action is required to place the interests and autonomy of older populations at the fore, to achieve the best quality of life possible. This radical action is not against drugs or their prescription, nor against drug companies, but against the many forces that, in aggregate, can lead to damaging or unwanted overmedication of the elderly.

As the portion of older subpopulations with complex morbidity expands, many warn that we are ill equipped intellectually, economically, and professionally to face this global challenge, in general, and the IMUP epidemic, in particular \[[@CR36], [@CR45]--[@CR50]\]. We therefore believe that current global trends in healthcare require assertive and coordinated action against IMUP. We present the first position statement of IGRIMUP (International Group for Reducing Inappropriate Medication Use & Polypharmacy) on the international co-operative effort, and recommendations for actions needed to prevent and counter IMUP and its drivers globally.

Main Approaches for Reducing Inappropriate Medication Use and Polypharmacy and Their Clinical Efficacies {#Sec2}
========================================================================================================

Many studies report on tools and strategies that have attempted to reduce IMUP. However, the global increase in the IMUP epidemic indicates that their efficacy is limited. There is inadequate information about the beneficial effect of these approaches on health outcomes, such as mortality, morbidity, function, cognition, patient well-being, healthcare services' utilization, and cost. A 2010 cohort study of multiple medication discontinuation using a 'consecutive patient' sampling frame \[[@CR50]\] is often referenced in the literature on polypharmacy as supporting the benefical health outcomes of using a general approach to drug discontinuation in community-dwelling patients. A further cohort study suggests long-term health benefits from drug discontinuation, compared with controls who declined deprescribing \[[@CR51]\]. These prospective studies achieved medication reductions and apparent benefits to health outcomes while measuring potential adverse effects, but were not randomized controlled trials. Studies in long-term residential care settings show that medications can be reduced but have yet to demonstrate beneficial outcomes, aside from a reduction in falls in those who have already had a fall \[[@CR52], [@CR53]\]. Other evidence of potential benefit is based on retrospective assessments of explicit lists of 'drugs to avoid', comparing these with admissions for ADEs to determine the sensitivity in predicting such events. One review concluded that evidence for health outcomes from pharmacist and physician based interventions to reduce polypharmacy is limited and conflicting, and recommended randomized controlled trials evaluating multidisciplinary interventions and clinical outcomes across different settings \[[@CR54]\].

We present the main methods suggested to improve IMUP and briefly note where successful clinical outcomes are achieved by some of them. These methods are usually categorized as explicit criteria-based tools (some computer assisted) and implicit judgment-based tools.

Computer-Assisted Digital Tools {#Sec3}
-------------------------------

A variety of computer programs have been developed in many countries to ease application of the explicit criteria to detect IMUP. In countries with full medication information in an electronic medical record, these systems may provide alarms that alert clinicians to a variety of potential drug interactions as they turn on their computers and try to prescribe new drugs \[[@CR55]\]. However, a systematic review of 10 studies of computerized physician order entry with clinical decision support showed a mixed effect on the reduction of ADEs \[[@CR56]\]. There are suggestions that automatic messages, particularly where there are many alerts and more repeated alerts, lead to reminder fatigue and insensitivity \[[@CR57]\]. Others warn that relying too much on computers, where decision support is single-disease oriented, may be misleading or harmful to older patients \[[@CR50], [@CR58]\].

Explicit Tools {#Sec4}
--------------

Explicit tools include lists of drugs to avoid or specific indicators of inappropriate medication use. A comparison of seven tools failed to show close similarities \[[@CR59]\]. The most widely used are the Beers criteria and the Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) \[[@CR60]--[@CR66]\]. Both were updated in 2015. The criteria divide potentially inappropriate medications into: medications to avoid prescribing; to avoid in certain circumstances; and to be used with caution. Following the Beers initiative in 1991, other country-specific lists were established: in Germany, PRISCUS (Latin for 'old and venerable') \[[@CR67]\] and the Fit for the Aged (FORTA); in France, a consensus panel list \[[@CR68]\]; in Norway, the Norwegian General Practice (NORGEP) list \[[@CR69]\]; in Canada, the Improving Prescribing in the Elderly Tool (IPET) \[[@CR70]\]; and others \[[@CR71], [@CR72]\], including in Australia \[[@CR73], [@CR74]\] and Thailand \[[@CR75]\]. In the USA, Assessing Care of Vulnerable Elders (ACOVE) \[[@CR76], [@CR77]\], the Health Care Financing Administration expert consensus panel drug utilization review criteria \[[@CR78]\], and Geriatric Risk Assessment MedGuide (GRAM) \[[@CR79]\] have also been developed.

Other scales specifically identify the anticholinergic burden of medications. Among the multiple scales developed to assess anticholinergic burden, the Drug Burden Index seemed to best predict adverse health outcomes \[[@CR80]\].

The Beers criteria has not yet been evaluated in a randomized controlled trial and, therefore, the extent of the lists effect in decreasing ADEs, morbidity, mortality, hospitalization and/or costs is uncertain. Analysis in a prospective cohort study shows modest sensitivity in predicting hospital admissions as a result of ADEs \[[@CR65]\]. Similarly, while applying STOPP/START criteria in older inpatients significantly improves the appropriateness of prescribing \[[@CR64]\] and could potentially reduce avoidable ADEs that may cause urgent hospitalization \[[@CR65], [@CR81]\], the tool has not yet been prospectively tested in the primary care setting and its effect on long-term outcomes is yet to be described. These lists are limited by their single drug/disease-oriented approach, and require regular updating.

Applying the Geriatric Risk Assessment MedGuide (GRAM) tool in long-term care was proven efficacious in reducing the rate of delirium, hospitalizations, and mortality resulting from ADEs in newly admitted residents \[[@CR79]\]. However, other clinical outcomes were not assessed and it has not yet been prospectively tested in the primary care setting.

'Fit for the Aged Criteria' (FORTA) combines both negative and positive labeling based on individual indications. It ranks drugs into four groups depending on evidence for safety, efficacy, and overall age appropriateness: (A) indispensable with obvious benefit; (B) proven efficacy but limited effects or possible safety concerns; (C) questionable efficacy or safety; (D) avoid \[[@CR82]\]. A randomized trial to validate FORTA in hospitalized geriatric patients was associated with an improvement in medication quality and a reduction in ADEs \[[@CR83]\]. Its effect on overall patient outcomes is not yet tested beyond feasibility studies \[[@CR84]\].

Other evidence of the potential benefit of explicit tools is based on retrospective assessments that use lists of 'drugs to avoid' and compare these with admissions for ADEs to determine the sensitivity in predicting (and therefore their potential to prevent) such events. These studies provide retrospective epidemiological data, but again, do not supply adequate unbiased proof that is required to understand the benefits of prospective application of these lists. There are other ongoing positive efforts to develop frameworks that (1) guide drug review; (2) reduce the harms of polypharmacy; and (3) advance single drug class deprescribing guidelines \[[@CR50], [@CR63], [@CR85]--[@CR87]\].

Implicit Approaches {#Sec5}
-------------------

To judge medication appropriateness, implicit approaches take into consideration research data, clinical circumstances, and patient/family preferences \[[@CR88], [@CR89]\]. Implicit approaches are less algorithmic and require much more time, knowledge, and judgment. This more complex approach is better suited to multimorbidity and to a shared decision-making model. However, the complexity of this approach creates problems for study design and relatively few studies have been carried out to assess efficacy and safety.

### Comprehensive Geriatric Assessment {#Sec6}

Comprehensive Geriatric Assessment (CGA) is a thorough evaluation of the older patient's characteristics, cognition, function, medical conditions, and social situation, which is used to identify problems and appropriately manage them through individualized care plans \[[@CR90]\]. Though there is variation in the execution of the CGA, drug review is an integral component, with the minimal requirement of medication count and assessment, preferably at each visit and at least annually \[[@CR76]\]. If time limitation is a concern, the minimal requirement is to focus on those drugs with the highest risk  or highest benefit \[[@CR28]\]. Multidisciplinary team approaches using the CGA in frail hospitalized older adults have been shown to significantly reduce serious ADEs and IMUP, when compared with usual care \[[@CR91]\]. Therefore, the CGA in itself may serve as an important tool for reducing IMUP \[[@CR88], [@CR89]\].

### Medication Appropriateness Index {#Sec7}

The Medication Appropriateness Index is a judgment-based process measure of prescribing appropriateness that assesses 10 elements of prescribing: indication, effectiveness, dose, correct directions, practical directions, drug--drug interactions, drug--disease interactions, duplication, duration, and cost. The Medication Appropriateness Index is the only implicit tool with validated inter-rater reliability \[[@CR92]\]. In heterogeneous smaller studies, the Index reduced ADEs compared with usual care \[[@CR93]\], but the tool has not been extensively used in larger settings.

### Prescribing Optimization Method {#Sec8}

The Prescribing Optimization Method is based on six questions: Is undertreatment present and the addition of medication indicated? Does the patient adhere to his/her medication schedule? Which drugs can be withdrawn or which drugs are inappropriate for the patient? Which adverse effects are present? Which clinically relevant interactions are to be expected? Should the dose, dose frequency, or form of drug be adjusted? \[[@CR94]\].

### SMART (Specific, Measurable, Acceptable, Realistic, and Time-framed) Tool {#Sec9}

The SMART (Specific, Measurable, Acceptable, Realistic and Time-framed) Tool is a method for reviewing complex geriatric drug regimens. It consists of 10 questions that draw attention to the appropriateness and safety of the drug plan. Therapeutic objectives are developed to improve quality of life, which the authors of the tool believe lead to a better understanding of geriatric clinical pharmacology, the special needs of older patients, and appropriate use of healthcare resources \[[@CR95]\].

### Patient-Focused Drug Surveillance {#Sec10}

Patient-focused drug surveillance was developed in Swedish nursing homes \[[@CR96]\]. The intervention involved a physician-led, patient-focused approach that optimizes medication therapy and reduces polypharmacy by taking the patient's health conditions into account. This approach advocates for a discussion of the benefits and risks of drug therapy with frail older people, accompanied by close monitoring and re-evaluation.

### CRIME (CRIteria to Assess Appropriate Medication Use Among Elderly Complex Patients) {#Sec11}

CRIME (CRIteria to assess appropriate Medication use among Elderly complex patients) offers 19 explicit recommendations on pharmacological treatments of only 5 common conditions (diabetes mellitus, hypertension, congestive heart failure, atrial fibrillation, and coronary heart disease). In line with vulnerability characteristics, CRIME takes into consideration complex aspects of aging (i.e. limited life expectancy, functional/cognitive impairments, and geriatric syndromes) that may negatively affect a drug's benefit/risk ratio and therefore reduce its efficacy \[[@CR97]\].

### PATH (Palliative and Therapeutic Harmonization) Program {#Sec12}

The PATH (Palliative and Therapeutic Harmonization) program was developed in Canada \[[@CR98]\]. One goal of this program is to achieve frailty-specific treatment guidelines to replace conventional clinical practice guidelines using an evidence review of common chronic conditions, such as hypertension, diabetes, and statin use for the prevention of cardiovascular disease \[[@CR99]--[@CR101]\]. The guidelines consider the clinical relevance of commonly accepted outcomes when there is frailty and suggest that even the outcome of reduced mortality may not be relevant with frailty owing to multiple competing risks for mortality. Based on an evidence review, the panel of experts conclude that rigid blood pressure, serum glucose, and cholesterol targets may be harmful in patients with severe frailty.

### 10-Step Discontinuation Guide {#Sec13}

The 10-Step Discontinuation Guide was formulated by Scott et al. and synthesizes suggestions and guidance raised in other frameworks \[[@CR28], [@CR86], [@CR102], [@CR103]\]. The guide recommends a case-specific framework for each patient, with confirmed face validity showing that doctors who used the guide suggested more drugs for discontinuation for a hypothetical case \[[@CR104]\].

### Good Palliative Geriatric Practice Algorithm {#Sec14}

The Good Palliative Geriatric Practice Algorithm is a proactive process that simultaneously discontinues as many 'non-life saving' medications as possible where there is an absence of evidence in older people. Attention is paid to a patient's circumstances and preference for care, and to providing follow-up monitoring (see Fig. [1](#Fig1){ref-type="fig"}) \[[@CR50]\]. In nursing homes, the discontinuation of 2.8 drugs per patient led to a significant 24% reduction in mortality and 18% in referral to acute care facilities \[[@CR105]\]. In community-dwelling elderly individuals, discontinuation of 4.4 drugs per patient led to an improvement of global health and well-being in 88% of the patients; only 2% of the discontinued drugs had to be re-administered and no significant adverse events were recorded as a result of deprescribing \[[@CR50]\]. This approach is translatable into any setting; but requires knowledge of the limitations of standard guidelines. A longer follow-up (\> 3 years) cohort study showed significantly better clinical outcomes in older people undergoing multiple deprescribing, compared with those who did not, suggesting benefits are sustained \[[@CR51]\].Fig. 1Good Palliative Geriatric Practice Algorithm

Moving Forward {#Sec15}
==============

"\"Where is the Wisdom We Have Lost in Knowledge?\""This phrase, from TS Elliott's *Choruses from The Rock,* reminds us that the competent use of multiple medicines requires the application of wisdom, based on a critical understanding of the limitations and generalizability of research and of patient circumstances and preferences. The original definition of evidence-based medicine (EBM) stated: "*Evidence*-*based medicine is the integration of best research evidence with clinical expertise and patient values*" \[[@CR106]\]. The EBM diagram shows how these concepts are integrated using clinical judgment. More recently evidence-based medicine has been reconfigured as single disease guideline adherence, whereby evidence largely encourages clinicians to start medications, but the integration of clinical judgment and patient-centered care are lost. In this situation variation may be seen as poor practice.

The cornerstone of this position statement is that without evidence of definite and relevant benefit, when prescribing for many older patients 'less is more'. The approach differs from standard guidance as the focus here is on what, when, and how to stop, rather than on when to start medications/interventions. The scope can be extended beyond frailty to include many subpopulations with multimorbidity, disability, or limited life expectancy. It extends beyond the list-based approach of any explicit tool.

Our principal goal is to promote a return to the original concept of EBM and restore the physician's role to one of a professional providing care, rather than a disease or algorithm technician. This role requires integration of patient preference and context, clinical judgment, and scientific data (where it exists), using a drug prescribing approach that can be customized to each older adult in a fashion aligned with patient-centered medicine ideals. A return to the more nuanced EBM framework, as described, will produce variation in care; but consistency in care is not synonymous with best care.

Most elderly patients have not had a formal review of their long-term medications and there is evidence that most patients, if asked, would like to reduce their medications and there is some evidence that patient-directed approaches to reducing single medicines can be effective \[[@CR107]--[@CR109]\]. The potential benefits of medication review to healthcare systems and patients are substantial and include reduced drug costs, ADEs, morbidity, and hospitalizations. Reducing IMUP should be a shared goal of the highest urgency that requires an integrated international effort.

There is a growing call for a medical system that better serves patients with multimorbidity \[[@CR36], [@CR58], [@CR110], [@CR111]\]. Barriers to addressing inappropriate medication use derive from the  limitations of research; an inadequate framework for the clinical care of patients with polypharmacy, performance measures and incentives that focus on starting but not stopping medications; commercial influences; health system design; inadequate education about medication risks; and insufficient funding, all of which impact prescribers, pharmacists, and patients. Addressing these barriers will require changes to medical education, research practice, diagnostic frameworks, measures of quality, and policy \[[@CR36], [@CR58], [@CR112]--[@CR114]\].

10 Recommendations of the International Group for Reducing Inappropriate Medication Use & Polypharmacy {#Sec17}
------------------------------------------------------------------------------------------------------

We make 10 recommendations for action and 12 recommendations for research.

*Individual and System Approaches to Inappropriate Medication Use and Polypharmacy*

Review the medications of all older adults with an eye to deprescribing, particularly those who are vulnerable to the adverse effects of medication.

Patients with polypharmacy deserve special attention. Consideration of medication reduction does not mean that medication reduction is appropriate for everyone. Likewise, after stopping a medication, the need to reintroduce that medication should not be seen as a failure.2.Before initiating a potentially 'appropriate' medication, consider the validity of the evidence based on patient characteristics and preferences.

Clinicians should bear in mind that disease-specific guidelines (and perceptions of 'under-prescribing') are driven by data from trials that almost always exclude (or do not separately evaluate) older adults, particularly those with vulnerability characteristics. When faced with polypharmacy, patients can be overwhelmed with the burden of treatment, which can compromise adherence. Thus, medications may need to be prioritized, recognizing that using all potentially 'helpful' medications may not be appropriate. Deprescribing based on the paradigm described may lead to labels of 'under-prescribing', but needs to be reframed as ideal prescribing in this context.3.Consider each medication for potential withdrawal, extending beyond standardized lists.

Many unnecessary and inappropriate medications for an individual are not included in lists of 'potentially inappropriate medications' \[[@CR50]\].4.Employ mixed implicit and explicit approaches to polypharmacy.

Explicit criteria contribute to the detection of IMUP and are useful support systems, but inadequate on a stand-alone basis. Drugs-to-avoid criteria are insufficiently accurate, focus only on the more common causes of ADEs, and may provide false reassurance: prescribing 10--15 'non-list' medications to patients is still likely to do more harm than good \[[@CR50], [@CR59], [@CR115]--[@CR117]\].5.Address the underrepresentation of older patients in clinical trials.

Older adults are largely excluded from randomized controlled trials; and those that are included are non-representative of an older population with multimorbidity \[[@CR118]--[@CR122]\]. Randomized controlled trial findings may, thus, overestimate the benefit-risk balance in favor of increased prescribing in the group least able to tolerate it. This approach is antithetical to good healthcare and is likely to increase health inequity \[[@CR111], [@CR123]--[@CR125]\]. Beyond recruitment strategies, the impact of underrepresentation/misrepresentation of older patients in trials might be at least partially addressed by incorporating stratified randomization and analysis, where possible. However, trial participation is disproportionately burdensome to patients with physical and cognitive limitations, who may also be unable to consent. Thus, approaches to enhance the enrollment of older adults must be complemented by explicit recognition that trial findings often overstate benefit over risk in older adults.

We also need a better understanding of the dose--effect curve and benefit/risk ratio of drugs used by older adults and especially for the subpopulation of older adults with frailty and multimorbidity. While observational studies contribute to our understanding of how treatment effects may be different in older age groups, on balance multiple concurrent medication use in older adults is a global experiment with little data collection. We need data on the overall health effects of this type of prescribing.6.Acknowledge and address commercial influences on polypharmacy: trial results should not be implemented in older adults unless access to all available patient-level data is provided. Appropriate outcome measures should be required before licensing indications that include older populations.

The degree to which commercial interests can potentially distort scientific data is well documented \[[@CR126]--[@CR131]\]. Trials can be structured to provide commercially favorable results and there is limited access to patient-level trial and adverse-event data, which are grounds for precautionary prescribing \[[@CR132]\]. Use of intermediate outcomes, publication bias, and overhyping of new or immature research results by media and pharmaceutical companies result in a research narrative that overestimates efficacy, underestimates harms, and fuels IMUP \[[@CR133]--[@CR135]\]. Evidence bias is commonly compounded by biased interpretation, where key opinion leaders have industry conflicts of interest \[[@CR136]\].7.Medical education needs a stronger focus on IMUP and its potential negative impact. Education about generalist approaches to multimorbidity should teach prioritization skills and aim to improve the clinician\'s understanding of the strengths and weaknesses of evidence and how best to apply standard models of care to vulnerable older adults with multimorbidity.

Currently these topics are inadequately emphasized in the curriculum to doctors, nurses, and pharmacists \[[@CR137]\] with insufficient education about the harm of polypharmacy, specific drug-class ADEs, the importance of medication reviews, and how specialty prescribing may increase IMUP and lead to prescribing cascades \[[@CR138], [@CR139]\].8.Medical training should review methods to stop treatments and provide equal attention to drug side effects and benefits.

When systematically discontinuing medications, physicians face multiple barriers, including fear of lawsuits, uncertainty about the best approach to combat IMUP, and lack of evidence-based studies on why, when, and how to stop medications \[[@CR58], [@CR140], [@CR141]\]. Most patients would be agreeable to reducing medication numbers, if recommended. However, when elderly patients/families want to reduce the drug load, they are pressured not to discontinue medications \[[@CR141], [@CR142]\]. Providing more balanced communication on risk and benefit, such as reviewing numbers needed to treat along with the number not benefiting, may help. Likewise, the generalizability of accepted outcomes such as all-cause mortality for elderly individuals could be discussed.9.When patients have multimorbidity, the single disease model (and its incentivization) should be spurned.

About half of people over 65 years of age have at least three coexisting chronic conditions and one in five has five or more \[[@CR143], [@CR144]\]. The single disease approach with adherence to clinical guidelines for each illness make polypharmacy and inappropriate medication use inevitable. Boyd et al. \[[@CR123]\] demonstrates this clearly: a patient experiencing five chronic conditions will receive 19 doses of 12 different medications, taken at five times during the day, carrying the risk of ten attendant interactions and adverse events. Quality measures that assess care on a single disease basis might rate this compliance with guidelines as \"good care\" but what appears measurably better is meaningfully worse for the patient. When performance pay or professional re-certifications are linked to guideline adherence, physicians may feel coerced into persuading patients to follow treatments that do not serve their best interests.

A single disease-by-disease approach obscures the multimorbid patient's individual pattern of symptoms and overrides their preferences for care. Data also suggest that treatments that focus on preventing single diseases at the end of the survival curve may simply change the cause of death and morbidity without making life longer or better; in essence, altering the manner of dying rather than the quality of living \[[@CR145]\]. Efforts to reframe guidance in terms of multimorbidity also note that support for preventive drugs for single diseases weakens as life expectancy decreases and that the additional benefit provided by individual drugs may reduce (or reverse) when combined \[[@CR146]\].10.Decisions in older complex patients should routinely consider expected survival and quality of life, giving the highest priority to patient/family preferences.

One physician should co-ordinate decisions within a shared framework (preferably in a generalist setting suited to consideration of multimorbidity and polypharmacy ideally with a pharmacist partner). Care for patients with multimorbidity should balance the burden of treatment, potential to benefit, potential harms, and personal priorities. The term 'personalized medicine' could be re-harnessed to describe these considerations.

Many important research and clinical needs arise from these 10 recommendations; we have proposed 12 polypharmacy research priorities in Table [2](#Tab2){ref-type="table"}.Table 212 polypharmacy research priorities1.Clarify the risks and benefits of different approaches to reduce polypharmacy using patient-relevant outcomes such as all-cause mortality, morbidity, function cognitive status, and healthcare utilization and cost2.Identify subgroups that will most benefit and those that may not3.Determine the reversibility of the negative health effects of inappropriate medication use and polypharmacy4.Clarify the effect of stopping treatments that have been used for many years5.Consider the effects of different clinical care funding models on strategies to address polypharmacy6.Define core important outcomes in treatment trials for drugs used in multimorbidity that assess risks and benefits based on patient and system-relevant domains7.Research, synthesize, and review the relative benefits and risks of different treatment options for individual chronic diseases, including non-pharmaceutical treatments8.Research, synthesize, and review the evidence on how and in whom to stop individual drugs9.Develop tools to assess the capacity for, and burden of, treatment in multimorbidity10.Develop tools that can aid the detection and management of drug adverse effects11.Assess different approaches to incorporating patient priorities, including in cognitive impairment12.Research optimal dosing in older adults

Conclusions {#Sec19}
===========

Reducing IMUP should be a high priority target. The morbidity and mortality attributed to the adverse effects of IMUP underscore this imperative. Studies suggest benefit from judicious deprescribing that may be equivalent to benefits achieved from medical treatments. Our goal is to promote a return to the original concept of EBM that integrates patient preference, context, clinical judgment, and scientific data (where it exists). There is a pressing need to reconceptualize the framework of medical care to better serve patients with multimorbidity, which will require shifts in medical education, quality measures, and policy. To reverse this epidemic of iatrogenic morbidity and mortality, an integrated global effort from health professionals, policy makers, and consumers is required.
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